D Maggs
Overview
Explore the profile of D Maggs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdul-Ghani M, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, et al.
Diabetes Obes Metab
. 2014 Nov;
17(3):268-75.
PMID: 25425451
Aim: To test our hypothesis that initiating therapy with a combination of agents known to improve insulin secretion and insulin sensitivity in subjects with new-onset diabetes would produce greater, more...
2.
Buse J, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, et al.
Diabetes Obes Metab
. 2014 Oct;
17(2):145-51.
PMID: 25323312
Aims: The recent type 2 diabetes American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) position statement suggested insulin is the most effective glucose-lowering therapy, especially when glycated haemoglobin...
3.
Paul S, Best J, Klein K, Han J, Maggs D
Diabetes Obes Metab
. 2012 Apr;
14(9):826-34.
PMID: 22510305
Aim: Treatment of patients with type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonist exenatide has showed improvements in glycaemic control coupled with weight loss and lowered blood pressure (BP)....
4.
Fineman M, Cirincione B, Maggs D, Diamant M
Diabetes Obes Metab
. 2012 Jan;
14(8):675-88.
PMID: 22233527
Glucagon-like peptide-1 (GLP-1), a gut-derived hormone secreted in response to nutrients, has several glucose and weight regulating actions including enhancement of glucose-stimulated insulin secretion, suppression of glucagon secretion, slowing of...
5.
Maggs D, Macdonald I, Nauck M
Diabetes Obes Metab
. 2007 May;
10(1):18-33.
PMID: 17490426
The gastrointestinal tract is increasingly viewed as a critical organ in glucose metabolism because of its role in delivering glucose to the circulation and in secreting multiple glucoregulatory hormones that,...
6.
Ratner R, Maggs D, Nielsen L, Stonehouse A, Poon T, Zhang B, et al.
Diabetes Obes Metab
. 2006 Jun;
8(4):419-28.
PMID: 16776749
Aim: The ability of the incretin mimetic exenatide to improve glycaemic control and reduce body weight was assessed over 82 weeks in patients with type 2 diabetes failing to achieve...
7.
8.
Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C
Metabolism
. 2003 Dec;
52(12):1638-42.
PMID: 14669170
An unresolved problem in the management of type 2 diabetes is that improvement of glycemic control with insulin, insulin secretagogues, and insulin sensitizers is often accompanied by undesired weight gain....
9.
Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, et al.
Diabetes Obes Metab
. 2003 Nov;
5(6):408-14.
PMID: 14617226
Aim: Two long-term, randomized, double-blind, placebo-controlled clinical trials in insulin-using patients with type 2 diabetes, spanning a wide range of baseline glycaemic control, have shown that the addition of pramlintide,...
10.
Chang E, Galle L, Maggs D, Estes D, Mitchell W
J Virol
. 2000 Nov;
74(24):11832-40.
PMID: 11090183
Herpetic stromal keratitis (HSK) is an inflammatory disease of the cornea that often results in blindness. It is mediated by a host immune response which is triggered by herpes simplex...